Laboratory investigationInterventional Therapy of Head and Neck Cancer with Lipid Nanoparticle–carried Rhenium 186 Radionuclide
Section snippets
Head and Neck SCC Xenografts in Nude Rats
Animal experiments were performed according to the National Institutes of Health Animal Care and Use Guidelines and were approved by our institutional animal care committee. During each animal handling procedure, animals were anesthetized by inhalation of 1%–3% isoflurane (Vedco, Saint Joseph, Missouri) in 100% oxygen with use of a veterinary inhalant anesthesia machine (Bickford, Wales Center, New York).
The head and neck SCC xenograft model used here has been previously reported (18). In
Tumor Volumes in 186Re-liposome Treatment Group and Control Groups
On the day of treatment infusion (ie, day 0; average body weight, 238.1 g ± 35.9), the average tumor volumes for groups 1, 2, 3, and 4 were 1.50 cm3 ± 0.52, 1.69 cm3 ± 0.43, 1.79 cm3 ± 0.39, and 1.72 cm3 ± 0.45, respectively. Figure 1a shows the average tumor volumes for each treatment group over the duration of the study. The average tumor volume of the 186Re-liposome treatment group decreased to 87.7% ± 20.1% of the pretreatment volume by day 14 (P < .001 vs control groups). The rate of tumor
Discussion
Local 186Re retention in the tumor was much higher when delivered by a liposome nanocarrier, resulting in a 150-fold greater tumor-absorbed radiation dose in the 186Re-liposome group than in other 186Re groups. This high dose resulted in drastically reduced tumor size and rate of tumor growth in 186Re-liposome–treated animals. A better intratumoral dispersion with 186Re-liposomes may have also contributed to the effective tumor therapy (10). Observations of the 186Re-liposome–treated tumors
References (33)
- et al.
Radionuclide therapy
Lancet
(1999) - et al.
Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection
Int J Pharm
(2006) - et al.
A novel liposome radiolabeling method using 99mTc-“SNS/S” complexes: in vitro and in vivo evaluation
J Pharm Sci
(2003) - et al.
Factors affecting survival in patients with oral cancer: an Australian perspective
Int J Oral Maxillofac Surg
(2005) - et al.
Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats
Otolaryngol Head Neck Surg
(2006) Colorimetric determination of phospholipids with ammonium ferrothiocyanate
Anal Biochem
(1980)Biological research in the evolution of cancer surgery: a personal perspective
Cancer Res
(2008)- et al.
The potential of intratumoural unsealed radioactive source therapy
Eur J Nucl Med
(2001) - et al.
Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond
CA Cancer J Clin
(2005)
Technology insight: image-guided therapies for hepatocellular carcinoma—intra-arterial and ablative techniques
Nature Clin Pract
Radionuclides and carrier molecules for therapy
Phys Med Biol
Beta dose point kernels for radionuclides of potential use in radioimmunotherapy
J Nucl Med
An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases
Cancer
Recent advances with liposomes as pharmaceutical carriers
Nature Rev Drug Discov
Impact of nanotechnology on drug delivery
ACS Nano
Cited by (48)
Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine
2019, Advanced Drug Delivery ReviewsThe future of mesenchymal stem cell-based therapeutic approaches for cancer – From cells to ghosts
2018, Cancer LettersCitation Excerpt :Overall, MSCs can be loaded with a broad spectrum of anti-cancer agents [125]. To do so, multiple packaging methods have been described, ranging from silica nanorattles [126] to liposomes [127]. All approaches are relying on MSCs as efficient carriers.
Spatiotemporally photoradiation-controlled intratumoral depot for combination of brachytherapy and photodynamic therapy for solid tumor
2016, BiomaterialsCitation Excerpt :In a related CED study, free drug concentration dropped by 25% at the injection site two hours after delivery and was decreased 10-fold at points 3 mm away [11]. In a second study, only 40% of initial dose of liposomal 186Re was retained in the tumor after 4 h [12]. To address the issue of intratumoral retention, stimulus-responsive polymers have gained popularity as improved drug delivery vehicles.
Nanoplatforms: The future of oral cancer treatment
2023, Health Science ReportsLipid nanoparticle-based formulations for high-performance dentistry applications
2023, Journal of Materials Chemistry B
This study was supported by National Cancer Institute/National Institutes of Health Grant R01 CA131039 to A.B. None of the authors have identified a conflict of interest.